Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Beta Bionics, Inc.NASDAQ: BBNX
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 13.5% from a year ago
Total equity stood at $271.25M at the end of Q1 FY2026, down 13.5% from a year earlier and down 5.7% from the prior quarter. Over 3 fiscal years it compounded at +180.7% a year.
Context
- Total equity amounted to 89.1% of total assets at the end of Q1 FY2026, down 3.7 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -13.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 287.61M USD
- Year-over-year change
- +278.4%
- 3-year CAGR
- +180.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 287.61M | +278.4% |
| FY2024 | 2024-12-31 | 76.01M | +29.7% |
| FY2023 | 2023-12-31 | 58.61M | +350.8% |
| FY2022 | 2022-12-31 | 13M | — |
Total Equity vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -13.5% is the 6th highest of 7, against a peer median of +0.4%.
- Total equity amounts to 89.1% of total assets for BBNX, versus a peer median of 40.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | DKK 221.28B DKK | +31.7% | +32.5% | 37.2% | |
MMEDMiniMed Group, Inc. Common Stock | Jul 2026 | $3.62B USD | — | — | 76.7% |
| Jun 2026 | $2.62B USD | +1.9% | +8.8% | 40.6% | |
| Jun 2026 | $1.42B USD | -2.8% | +47.1% | 44.9% | |
| Mar 2026 | $271.25M USD | -13.5% | +180.7% | 89.1% | |
| Mar 2026 | $238.28M USD | +70.3% | +9.7% | 88.6% | |
| Mar 2026 | $132.4M USD | -14.7% | -29.3% | 11.5% | |
| Mar 2026 | -$59.2M USD | -1.0% | — | 8.0% | |
| Peer median (excluding BBNX) | — | +0.4% | +9.7% | 40.6% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.